The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

In this webinar, Daryl Cole will share insights into the high-throughput screening and analysis of antibody binding and functional characterization.

Anti-C1q antibodies are highly prevalent among patients with IgG4-RD, particularly those with renal and skin manifestations.

"This research provides crucial insights into how the immune system functions in sickle cell disease," said Dr. Karina Yazdanbakhsh, Vice President and Director of Research at New York Blood Center ...

NASA astronaut Suni Williams was undertaking a repair on the ISS when she was photographed from Earth by an amateur ...

A study published in Science Advances reveals a novel strategy that allows tumors to evade the body’s immune response ...

By Tarun Sai Lomte A study finds that IN-006, a reformulated monoclonal antibody, is safe, well-tolerated, and delivers high ...